Credit Suisse’s Repros Therapeutics Inc. RPRX Stock Holding History

Credit Suisse’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-70,375	Closed	-$85K	–	4582
2015 Q4	$85K	Buy	+70,375	New	+$226K	﹤0.01%	4088
2015 Q3	–	Sell	-111,072	Closed	-$794K	–	4788
2015 Q2	$794K	Buy	111,072 +82,104	+283%	+$640K	﹤0.01%	3381
2015 Q1	$248K	Sell	28,968 -23,614	-45%	-$211K	﹤0.01%	3970
2014 Q4	$525K	Sell	52,582 -117,820	-69%	-$1M	﹤0.01%	3677
2014 Q3	$1.69M	Buy	170,402 +147,491	+644%	+$2.18M	﹤0.01%	2624
2014 Q2	$397K	Buy	22,911 +2,650	+13%	+$43.2K	﹤0.01%	3964
2014 Q1	$359K	Sell	20,261 -34,349	-63%	-$665K	﹤0.01%	3964
2013 Q4	$1M	Buy	54,610 +2,206	+4%	+$41.7K	﹤0.01%	3284
2013 Q3	$1.4M	Buy	52,404 +22,931	+78%	+$491K	﹤0.01%	2690
2013 Q2	$544K	Buy	+29,473	New	+$521K	﹤0.01%	3250

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Credit Suisse's RPRX Position: Q1 2016 in Review

Credit Suisse sold out of Repros Therapeutics Inc. (RPRX) in Q1 2016, closing a stake of 70,375 shares — an estimated $85K sold.

Credit Suisse first reported a position in RPRX in Q2 2013 and held it in 10 quarters. The position peaked at $1.69M in Q3 2014. 53 funds tracked by Wall St. Rank hold RPRX as of Q1 2016.

Credit Suisse reported no remaining Repros Therapeutics Inc. position as of Q1 2016 after selling out during the quarter.
Credit Suisse sold 70,375 Repros Therapeutics Inc. shares in Q1 2016, an estimated $85K.
Credit Suisse first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 10 quarters.
Credit Suisse's Repros Therapeutics Inc. position peaked at $1.69M in Q3 2014.
53 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2016.

Based on Credit Suisse's 13F filing for Q1 2016, filed 16 May 2016.